AKT1 and colorectal carcinoma: Moreover, the above downregulation was attenuated after treatment with PI3K/Akt activator, suggesting that ZJW reverses drug resistance in human CRC cells by blocking the PI3K/Akt/NF-κB signaling pathway and enhances the anti-apoptotic effect of oxaliplatin (Fig. 2).